{"id":"tocilizumab-sc","safety":{"commonSideEffects":[{"rate":"null","effect":"Increased risk of infections"},{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Hypersensitivity reactions"}]},"_chembl":null,"_fixedAt":"2026-03-30T12:49:29.906316","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to the interleukin-6 receptor, tocilizumab SC prevents the activation of the interleukin-6 receptor and subsequent signaling pathways, thereby reducing inflammation and modulating the immune response. This mechanism of action is particularly useful in treating conditions characterized by excessive inflammation, such as rheumatoid arthritis.","oneSentence":"Tocilizumab SC is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:54:19.048Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Juvenile idiopathic arthritis"}]},"_fixedFields":["pubmed(10)"],"trialDetails":[{"nctId":"NCT05169515","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-10-26","conditions":"Non-Hodgkin Lymphoma","enrollment":121},{"nctId":"NCT04910568","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2021-07-26","conditions":"Multiple Myeloma","enrollment":126},{"nctId":"NCT04246086","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2020-08-12","conditions":"Follicular Lymphoma","enrollment":237},{"nctId":"NCT04634552","phase":"PHASE2","title":"A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Janssen Research & Development, LLC","startDate":"2021-02-01","conditions":"Hematological Malignancies","enrollment":510},{"nctId":"NCT03424005","phase":"PHASE1, PHASE2","title":"A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-03-30","conditions":"Metastatic Breast Cancer","enrollment":792},{"nctId":"NCT05835986","phase":"PHASE1","title":"A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-12-18","conditions":"Systemic Lupus Erythematosus","enrollment":70},{"nctId":"NCT04940299","phase":"PHASE2","title":"Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-09-23","conditions":"Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Bladder Carcinoma","enrollment":35},{"nctId":"NCT05171647","phase":"PHASE3","title":"A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-04-25","conditions":"Non-Hodgkin Lymphoma","enrollment":208},{"nctId":"NCT05927571","phase":"PHASE1","title":"A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM)","status":"RECRUITING","sponsor":"Genentech, Inc.","startDate":"2023-08-10","conditions":"Relapsed or Refractory Multiple Myeloma","enrollment":120},{"nctId":"NCT05207670","phase":"PHASE2","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genentech, Inc.","startDate":"2022-02-01","conditions":"Non-Hodgkin Lymphoma","enrollment":320},{"nctId":"NCT05091424","phase":"PHASE1","title":"A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2022-03-07","conditions":"Chronic Lymphocytic Leukemia","enrollment":137},{"nctId":"NCT07108387","phase":"PHASE2","title":"Tocilizumab Discontinuation Versus Dose Reduction for Patients With Well-Controlled Giant Cell Arteritis","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2025-12-11","conditions":"Giant Cell Arteritis (GCA)","enrollment":78},{"nctId":"NCT04088396","phase":"PHASE3","title":"A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Years Old With Systemic Juvenile Idiopathic Arthritis (sJIA)","status":"RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2020-02-12","conditions":"Systemic Juvenile Idiopathic Arthritis","enrollment":58},{"nctId":"NCT05305066","phase":"NA","title":"Stand UP to Rheumatoid Arthritis (SUPRA)","status":"RECRUITING","sponsor":"Marie Hudson, MD","startDate":"2023-02-01","conditions":"Rheumatoid Arthritis","enrollment":75},{"nctId":"NCT06492837","phase":"PHASE2","title":"Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2024-10-23","conditions":"Follicular Lymphoma","enrollment":56},{"nctId":"NCT07077486","phase":"PHASE4","title":"Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease","status":"RECRUITING","sponsor":"Tongji Hospital","startDate":"2025-08-25","conditions":"Lupus or SLE, Interstitial Lung Disease, Systemic Lupus Erythematosus","enrollment":100},{"nctId":"NCT04616248","phase":"PHASE1","title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2023-01-09","conditions":"Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Prognostic Stage IV Breast Cancer AJCC v8","enrollment":14},{"nctId":"NCT03193190","phase":"PHASE1, PHASE2","title":"A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-07-05","conditions":"Pancreatic Adenocarcinoma","enrollment":341},{"nctId":"NCT03651518","phase":"PHASE2","title":"Personalized Therapies in Inflammatory Complex Disease","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-10-20","conditions":"Inflammatory Disease, Autoimmune Diseases","enrollment":32},{"nctId":"NCT06262477","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants","status":"COMPLETED","sponsor":"Biogen","startDate":"2024-01-02","conditions":"Healthy Volunteer","enrollment":300},{"nctId":"NCT03677154","phase":"PHASE1, PHASE2","title":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2019-05-23","conditions":"Diffuse Large B-cell Lymphoma","enrollment":188},{"nctId":"NCT04888221","phase":"PHASE3","title":"Efficacy of Tocilizumab in Association to Steroids in Giant Cell Arteritis With Cerebro-vascular Involvement","status":"ACTIVE_NOT_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-09-24","conditions":"Giant Cell Arteritis, Neurovascular Disorder","enrollment":66},{"nctId":"NCT05155345","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered Mosunetuzumab to Participants With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2022-01-11","conditions":"Systemic Lupus Erythematosus","enrollment":15},{"nctId":"NCT03671018","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-25","conditions":"B-cell Non-Hodgkin Lymphoma","enrollment":422},{"nctId":"NCT04066114","phase":"PHASE1, PHASE2","title":"Treg Modulation With CD28 and IL-6 Receptor Antagonists","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-11","conditions":"Living-Donor Kidney Transplant, Kidney Transplant Recipients","enrollment":24},{"nctId":"NCT05315713","phase":"PHASE1, PHASE2","title":"An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-05-10","conditions":"Non-Hodgkin Lymphoma, Follicular Lymphoma","enrollment":8},{"nctId":"NCT05219513","phase":"PHASE1","title":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2022-02-18","conditions":"Lymphoma, Non-Hodgkin","enrollment":53},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT04580121","phase":"PHASE1","title":"A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-11-04","conditions":"Acute Myeloid Leukemia","enrollment":59},{"nctId":"NCT03895879","phase":"PHASE4","title":"Use of Tocilizumab Drug Levels to Optimize Treatment in RA","status":"RECRUITING","sponsor":"Reade Rheumatology Research Institute","startDate":"2020-03-01","conditions":"Rheumatoid Arthritis","enrollment":98},{"nctId":"NCT03155347","phase":"PHASE3","title":"An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-08-02","conditions":"Rheumatoid Arthritis","enrollment":340},{"nctId":"NCT06048224","phase":"PHASE3","title":"Phase III Clinical Trial Comparing the Safety, Efficacy, and Immunogenicity of Recombinant Anti-interleukin-6 Receptor Humanized Monoclonal Antibody Injection in Combination With Methotrexate and Jamelor ® in the Treatment of Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Zhejiang Hisun Pharmaceutical Co. Ltd.","startDate":"2020-12-28","conditions":"Moderate to Severe Active Rheumatoid Arthritis","enrollment":669},{"nctId":"NCT05725434","phase":"PHASE3","title":"A Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P47 in Patients With Active Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2023-02-06","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT04551352","phase":"PHASE1","title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-10-28","conditions":"Cutaneous Melanoma, Uveal Melanoma, Mucosal Melanoma","enrollment":20},{"nctId":"NCT04239196","phase":"PHASE2","title":"Efficacy of Tocilizumab for the Treatment of Acute AION Related to GCA","status":"UNKNOWN","sponsor":"Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts","startDate":"2020-09-10","conditions":"Giant Cell Arteritis, Optic Ischaemic Neuropathy","enrollment":58},{"nctId":"NCT02165345","phase":"PHASE1","title":"Extension Study Evaluating the Safety and Efficacy of Subcutaneous Tocilizumab (RoActemra/Actemra) Administration in Systemic and Polyarticular-Course Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-16","conditions":"Juvenile Idiopathic Arthritis","enrollment":82},{"nctId":"NCT05188378","phase":"PHASE1","title":"A Study to Compare the Pharmacokinetics and Safety of CT-P47 and RoActemra in Healthy Subjects","status":"UNKNOWN","sponsor":"Celltrion","startDate":"2021-12-22","conditions":"Healthy Subjects","enrollment":300},{"nctId":"NCT04332094","phase":"PHASE2","title":"Clinical Trial of the Use of Tocilizumab for Treatment of SARS-CoV-2 Infection (COVID-19)","status":"UNKNOWN","sponsor":"Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau","startDate":"2020-04-02","conditions":"COVID-19","enrollment":276},{"nctId":"NCT01557374","phase":"PHASE4","title":"TOward the Lowest Effective DOse of Abatacept or Tocilizumab","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2012-04","conditions":"Rheumatoid Arthritis","enrollment":232},{"nctId":"NCT02660528","phase":"PHASE2","title":"Tocilizumab Augmentation in Treatment-Refractory Major Depressive Disorder","status":"TERMINATED","sponsor":"Brigham and Women's Hospital","startDate":"2016-04","conditions":"Major Depressive Disorder","enrollment":3},{"nctId":"NCT04322773","phase":"PHASE2","title":"Anti-il6 Treatment of Serious COVID-19 Disease With Threatening Respiratory Failure","status":"TERMINATED","sponsor":"Marius Henriksen","startDate":"2020-04-05","conditions":"Corona Virus Disease","enrollment":20},{"nctId":"NCT03202368","phase":"PHASE3","title":"An Extension Study to Evaluate Long-Term Safety of Subcutaneous (SC) Tocilizumab in Participants With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-10-25","conditions":"Giant Cell Arteritis","enrollment":3},{"nctId":"NCT03539484","phase":"PHASE1","title":"A Study of RO7172508 in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2018-07-04","conditions":"Solid Tumors","enrollment":26},{"nctId":"NCT03291457","phase":"","title":"A Study to Evaluate the Use of Glucocorticoids in Combination With Tocilizumab in Daily Clinical Practice","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-03-30","conditions":"Rheumatoid Arthritis","enrollment":101},{"nctId":"NCT03288584","phase":"","title":"Effects of Interleukin-6 Inhibition on Vascular, Endothelial and Left Ventricular Function in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"University of Athens","startDate":"2017-10-27","conditions":"Rheumatoid Arthritis, Inflammation","enrollment":60},{"nctId":"NCT02453256","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Tocilizumab in Participants With Systemic Sclerosis (SSc)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-11-20","conditions":"Systemic Sclerosis","enrollment":212},{"nctId":"NCT02608112","phase":"","title":"Study to Describe Real World Drug Retention Rate of the Tocilizumab at One Year","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-12-31","conditions":"Rheumatoid Arthritis","enrollment":291},{"nctId":"NCT01791153","phase":"PHASE3","title":"An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07-22","conditions":"Giant Cell Arteritis","enrollment":251},{"nctId":"NCT02402686","phase":"","title":"Non-Interventional Study of Tocilizumab Subcutaneous (SC) Monotherapy in Participants With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-05-20","conditions":"Rheumatoid Arthritis","enrollment":353},{"nctId":"NCT02682823","phase":"PHASE4","title":"Tocilizumab Real-Life Human Factors (RLHFs) Validation Study","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-03-21","conditions":"Rheumatoid Arthritis","enrollment":91},{"nctId":"NCT02648035","phase":"","title":"EMBRACE-SC: Observational Study of Subcutaneous (SC) Tocilizumab Alone or in Combination With Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-09-22","conditions":"Rheumatoid Arthritis","enrollment":200},{"nctId":"NCT03112213","phase":"","title":"Characterization of Non-Steroidal Anti-Inflammatory Drug (NSAID) Intake in Rheumatoid Arthritis (RA) Participants on Tocilizumab (RoACTEMRA®) Treatment","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-12","conditions":"Rheumatoid Arthritis","enrollment":135},{"nctId":"NCT02046603","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-03-04","conditions":"Rheumatoid Arthritis","enrollment":162},{"nctId":"NCT01941095","phase":"PHASE3","title":"A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-20","conditions":"Rheumatoid Arthritis","enrollment":100},{"nctId":"NCT02001987","phase":"PHASE3","title":"A Study of Tocilizumab (RoActemra) in Tocilizumab-Naive Participants With Rheumatoid Arthritis and Inadequate Response to Non-Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) and/or Biologic Therapy","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01","conditions":"Rheumatoid Arthritis","enrollment":139},{"nctId":"NCT02552940","phase":"","title":"An Observational Study to Evaluate the Clinical Effectiveness, Quality of Life, Safety and Tolerability of Tocilizumab (TCZ) in Patients With Rheumatoid Arthritis (RA) in Daily Clinical Practice","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-31","conditions":"Rheumatoid Arthritis","enrollment":140},{"nctId":"NCT02046616","phase":"PHASE3","title":"A Study of Subcutaneous (SC) Tocilizumab (RoActemra/Actemra) in Participants With Active Rheumatoid Arthritis (RA) and Inadequate Response to Disease-Modifying Anti-Rheumatic Drugs (DMARDs)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-28","conditions":"Rheumatoid Arthritis","enrollment":133},{"nctId":"NCT02534311","phase":"","title":"A Phase IV Study to Evaluate the Effect of Subcutaneous (SC) Tocilizumab Administered to Participants With Rheumatoid Arthritis (RA) Assessed Using Disease Activity Score (DAS28)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2015-10-13","conditions":"Rheumatoid Arthritis","enrollment":60},{"nctId":"NCT01995201","phase":"PHASE3","title":"A Study of Subcutaneous RoActemra/Actemra (Tocilizumab) as Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09","conditions":"Rheumatoid Arthritis","enrollment":401},{"nctId":"NCT01855789","phase":"PHASE3","title":"A Study of the Impact of Methotrexate (MTX) Discontinuation on the Efficacy of Subcutaneous (SC) Tocilizumab (TCZ) With MTX","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-11-07","conditions":"Rheumatoid Arthritis","enrollment":718},{"nctId":"NCT01904292","phase":"PHASE1","title":"A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-08-15","conditions":"Juvenile Idiopathic Arthritis","enrollment":52},{"nctId":"NCT01941940","phase":"PHASE3","title":"A Study to Evaluate Efficacy of Tocilizumab Administered as Monotherapy or in Combination With Methotrexate and/or Other Disease Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis (RA) Participants","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-09-05","conditions":"Rheumatoid Arthritis","enrollment":227},{"nctId":"NCT01768572","phase":"PHASE3","title":"To Evaluate The Safety of SAR153191 (REGN88) and Tocilizumab Added to Other RA Drugs in Patients With RA Who Are Not Responding to or Intolerant of Anti-TNF Therapy (SARIL-RA-ASCERTAIN)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2013-03","conditions":"Rheumatoid Arthritis","enrollment":202},{"nctId":"NCT01987479","phase":"PHASE3","title":"A Study on Safety and Efficacy of Tocilizumab (RoActemra/Actemra) Alone or in Combination With Non-Biologic Antirheumatics in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-30","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT01904279","phase":"PHASE1","title":"A Study of Subcutaneously (SC) Administered Tocilizumab (TCZ) in Participants With Polyarticular-Course Juvenile Idiopathic Arthritis (pJIA)","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2013-07","conditions":"Juvenile Idiopathic Arthritis","enrollment":52},{"nctId":"NCT01734993","phase":"PHASE3","title":"A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-10","conditions":"Rheumatoid Arthritis","enrollment":11},{"nctId":"NCT01772316","phase":"PHASE3","title":"A Long-Term Extension Study of WA22763 and NA25220 of Subcutaneous RoActemra/Actemra (Tocilizumab) in Patients With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":47},{"nctId":"NCT00965653","phase":"PHASE1","title":"A Study of Subcutaneously Administered Tocilizumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2009-08","conditions":"Rheumatoid Arthritis","enrollment":29},{"nctId":"NCT01418989","phase":"PHASE1","title":"A Study of Administration of RoActemra/Actemra (Tocilizumab) by Auto-injector Vs. Pre-filled Syringe in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-07","conditions":"Healthy Volunteer","enrollment":239},{"nctId":"NCT02678988","phase":"PHASE1","title":"A Study to Evaluate the Bioequivalence of Tocilizumab Following Subcutaneous Administration Via an Autoinjector (AI 1000-G2) Versus a Pre-Filled Syringe in Healthy Volunteers","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2016-02","conditions":"Healthy Volunteer","enrollment":189},{"nctId":"NCT01662063","phase":"PHASE3","title":"A Long-Term Extension Study of WA22762 and NA25220 of Subcutaneous (SC) Tocilizumab (TCZ) in Moderate to Severe Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2012-08","conditions":"Rheumatoid Arthritis","enrollment":218},{"nctId":"NCT01194414","phase":"PHASE3","title":"A Study to Compare Subcutaneous Versus Intravenous Administration of RoActemra/Actemra (Tocilizumab) in Participants With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":1262},{"nctId":"NCT02404558","phase":"PHASE1","title":"Single-dose Study to Describe the Safety of Sarilumab and Tocilizumab in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2015-05","conditions":"Rheumatoid Arthritis","enrollment":30},{"nctId":"NCT01232569","phase":"PHASE3","title":"A Study of RoActemra/Actemra (Tocilizumab) Given Subcutaneously in Combination With Traditional DMARDs in Patients With Moderate to Severe Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-03","conditions":"Rheumatoid Arthritis","enrollment":656},{"nctId":"NCT02097524","phase":"PHASE1","title":"Single-dose Study to Describe the Pharmacodynamics (PD) and Safety of Sarilumab (REGN88/SAR153191) and Tocilizumab in Adults With Rheumatoid Arthritis (RA)","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2014-03","conditions":"Rheumatoid Arthritis","enrollment":105},{"nctId":"NCT01283971","phase":"PHASE4","title":"A Study of RoActemra/Actemra (Tocilizumab) Versus Adalimumab in Combination With Methotrexate (MTX) in Patients With Moderate to Severe Active Rheumatoid Arthritis And an Inadequate Response to Treatment With Only One Tumor Necrosis Factor (TNF)-Inhibitor","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2011-05","conditions":"Rheumatoid Arthritis","enrollment":96}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"recentPublications":[{"date":"2025","pmid":"41367720","title":"Switch from Intravenous to Subcutaneous Formulation of Tocilizumab in Rheumatoid Arthritis: Retrospective Cohort Analysis and Systematic Literature Review.","journal":"Biologics : targets & therapy"},{"date":"2025 Dec 22","pmid":"40971533","title":"Real-world use of biologics for systemic juvenile idiopathic arthritis: Information from a Japanese hospital claims database.","journal":"Modern rheumatology"},{"date":"2024 Sep 1","pmid":"38552315","title":"Long-term efficacy and safety of subcutaneous tocilizumab in clinical trials of polyarticular or systemic juvenile idiopathic arthritis.","journal":"Rheumatology (Oxford, England)"},{"date":"2023 Dec","pmid":"36657742","title":"Subcutaneous Tocilizumab in Juvenile Idiopathic Arthritis Associated Uveitis.","journal":"Ocular immunology and inflammation"},{"date":"2023 Mar","pmid":"36062738","title":"Switching from intravenous tocilizumab to subcutaneous administration during COVID-19 pandemic: impact on treatment efficacy and patient satisfaction.","journal":"Clinical and experimental rheumatology"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["RoActemra/Actemra"],"phase":"phase_3","status":"active","brandName":"tocilizumab SC","genericName":"tocilizumab SC","companyName":"Hoffmann-La Roche","companyId":"hoffmann-la-roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Tocilizumab SC is an interleukin-6 receptor antagonist that blocks the action of interleukin-6, a cytokine involved in inflammation. Used for Rheumatoid arthritis, Juvenile idiopathic arthritis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}